Emerging Financing Alternatives for Life Sciences Companies: Opportunities and Pitfalls You Need to Know.
Life sciences businesses are now turning to alternative financing options to fund their growth. These include royalty financing, initial public offerings (IPOs), and collaborative arrangements. However, companies that enter these types of financing must be wary of potential drawbacks and reporting challenges. They must clearly understand and comply with the updated rules related to these alternatives. Counsel to businesses must develop an advanced strategic approach to leverage potentials and avoid legal issues.
Field of Study: Business Law
Live and Recorded CLE & CPE Webcasts in the Legal, Tax, Finance, Risk, Compliance and Human Resources Industries
Founded in November 2006, The Knowledge Group has established itself as a premier eLearning hub for Continuing Legal Education (CLE), Continuing Professional Education (CPE), and technology-focused webcasts. We equip lawyers, accountants, and industry professionals with expert-driven insights, timely regulatory updates, and practical strategies to help them stay ahead in an ever-evolving landscape.
Laurie A. Burlingame Partner Goodwin Procter LLP Laurie Burlingame is a partner in the firm’s nationally recognized Life Sciences Practice Group. She represents private and public companies across the spectrum of the life sciences industry, including pharmaceuticals, medical devices, diagnostics and biological materials. Ms. Burlingame also represents leading venture capital firms focused on the life sciences industry in connection with their portfolio company investments. Ms. Burlingame often serves as outside general counsel to her clients, closely advising management teams and boards of directors on a wide variety of matters throughout the company’s life cycle, including formation and founder issues, venture capital financings, public offerings, mergers and acquisitions, licensing transactions, strategic collaborations, commercial transactions, corporate governance, and other general corporate matters. _____________ Sara H. Shanti Partner Benesch Friedlander Coplan & Aronoff LLP Sara Shanti is a partner in Benesch’s Health Care & Life Sciences Practice Group. Sara represents health care providers and technology companies in matters related to data privacy and security, health care regulatory compliance, and mergers and acquisitions. Sara’s practice focuses on counseling clients on various digital health matters, including artificial intelligence, breach notification, mobile applications, and telemedicine. Sara’s experience includes advising clients on transferring data across multi-national borders, implementing compliance programs, launching health apps, and responding to federal investigations and security incidents, including ransomeware attacks. Her experience extends to consumer and minor patient rights, medical staff relationships, and transactional matters.
